Magnus Sundstrom
Overview
Explore the profile of Magnus Sundstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1040
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mezheyeuski A, Micke P, Martin-Bernabe A, Backman M, Hrynchyk I, Hammarstrom K, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771707
While the clinical importance of CD8+ and CD3+ cells in colorectal cancer (CRC) is well established, the impact of other immune cell subsets is less well described. We sought to...
2.
Aasebo K, Dragomir A, Sundstrom M, Mezheyeuski A, Edqvist P, Eide G, et al.
Front Oncol
. 2020 Mar;
10:8.
PMID: 32117703
Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for trial patients. New predictive and prognostic biomarkers validated in the general mCRC population are needed. Caudal-type homeobox 2...
3.
Nunes L, Aasebo K, Mathot L, Ljungstrom V, Edqvist P, Sundstrom M, et al.
Acta Oncol
. 2020 Jan;
59(4):417-426.
PMID: 31924107
We have reported that V600E mutations and microsatellite instability-high (MSI-H) are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC) patients than has been reported from clinical trials...
4.
Mezheyeuski A, Ponten F, Edqvist P, Sundstrom M, Thunberg U, Qvortrup C, et al.
Acta Oncol
. 2019 Nov;
59(3):284-290.
PMID: 31769323
Survival and response to therapy in patients with metastatic colorectal cancer (mCRC) are very heterogeneous. There is an unmet need for better markers of prognosis and treatment benefit for mCRC...
5.
Aasebo K, Dragomir A, Sundstrom M, Mezheyeuski A, Edqvist P, Eide G, et al.
Cancer Med
. 2019 May;
8(7):3623-3635.
PMID: 31070306
Background: Immunotherapy for patients with microsatellite-instable (MSI-H) tumors or BRAF-inhibitors combination treatment for BRAF-mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes...
6.
La Fleur L, Falk-Sorqvist E, Smeds P, Berglund A, Sundstrom M, Mattsson J, et al.
Lung Cancer
. 2019 Mar;
130:50-58.
PMID: 30885352
Objectives: Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique combinations of somatic molecular alterations in individual patients, as well as significant differences in populations across the world...
7.
Mathot L, Kundu S, Ljungstrom V, Svedlund J, Moens L, Adlerteg T, et al.
Cancer Res
. 2017 Jan;
77(7):1730-1740.
PMID: 28108514
The contribution of somatic mutations to metastasis of colorectal cancers is currently unknown. To find mutations involved in the colorectal cancer metastatic process, we performed deep mutational analysis of 676...
8.
Segerman A, Niklasson M, Haglund C, Bergstrom T, Jarvius M, Xie Y, et al.
Cell Rep
. 2016 Dec;
17(11):2994-3009.
PMID: 27974212
Intratumoral heterogeneity is a hallmark of glioblastoma multiforme and thought to negatively affect treatment efficacy. Here, we establish libraries of glioma-initiating cell (GIC) clones from patient samples and find extensive...
9.
Davanian H, Balasiddaiah A, Heymann R, Sundstrom M, Redenstrom P, Silfverberg M, et al.
Oncotarget
. 2016 Dec;
8(3):4530-4542.
PMID: 27965463
Ameloblastoma of the jaws remains the top difficult to treat odontogenic tumour and has a high recurrence rate. New evidence suggests that non-coding RNAs (ncRNAs) play a critical role in...
10.
Padhan N, Nordling T, Sundstrom M, Akerud P, Birgisson H, Nygren P, et al.
BMC Cancer
. 2016 Aug;
16(1):683.
PMID: 27562229
Background: The progression of colorectal cancer (CRC) involves recurrent amplifications/mutations in the epidermal growth factor receptor (EGFR) and downstream signal transducers of the Ras pathway, KRAS and BRAF. Whether genetic...